Study in Healthy Volunteers to Document Safety and Tolerability of Increasing Doses Pemirolast

Healthy Volunteers Clinical Trial

Official title:

An Open-label, Single Center, Phase I, Dose Escalation Study Investigating the Safety, Tolerability and Pharmacokinetics of Pemirolast in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02517372
• Other study ID #: RSPR-PE-006
• Status: Completed
• Phase: Phase 1
• First received: April 29, 2015
• Last updated: August 4, 2015
• Start date: October 2014
• Est. completion date: December 2014

Study information

• Verified date: August 2015
• Source: RSPR Pharma AB
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products Agency
• Study type: Interventional

Clinical Trial Summary

This study is a single-centre, open-label, dose escalation , safety, tolerability and pharmacokinetics (PK) study in healthy male and female subjects. The study include a screening day and a 5-day dosing period. Subjects will be enrolled in sequential cohorts and each cohort will include 8 subjects. there will be 24 subjects total included in the study. The duration of the clinical part of the study will be approximately 2 months.

Description:

Subjects meeting the eligibility criteria at screening will remain in the clinic from the evening preceding the first day of dosing (Day - 1) of the investigational medical product (IMP) and check out from the clinic 24 hours after the first dose administration of the IMP (in the morning of Day 2). Dose administration of the IMP in the evening of Day 2 and morning and evening dose for Days 3 and 4 will be performed at home. The subjects will check-in again in the morning of Day 5 and receive the last dose administration of the IMP and stay in the clinic 12 hours post dose. All subjects within the same cohort will receive the same dose of the IMP.

There will be 3 cohorts (dose-levels) with 8 subjects in each cohort corresponding to 24 subjects in total. Within a cohort the subjects will be dosed in groups of 4. There will be 24 hours between the dosing of the groups and 15 minutes between the dosing of the subjects in a group.

There will be an interval of approximately at least 1-week interval between the cohorts to allow time for compilation and evaluation of data for the Internal Safety Review Committee meeting.

Subsequent cohorts will be administered increasing doses until either the maximum tolerated dose (MTD) or the study maximum dose (SMD) has been reached.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Written informed consent, healthy subjects aged 19-65 years

Exclusion Criteria:

• Significant concurrent disease or medical conditions that are deemed to interfere with the safety or pharmacokinetics of CRD007 conduct of the trial

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• CRD007

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
RSPR Pharma AB

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with Adverse Events as a measure of Safety and Tolerability		Change from baseline to day 5 (12 hours post dose)	No
Primary	Results of physical examination as a composite outcome measure of Safety and Tolerability		Change from baseline to day 5 (12 hours post dose)	No
Primary	ECG recording as a measure of Safety and Tolerability		Change from baseline to day 5 (12 hours post dose)	No
Primary	Vital signs (Blood Pressure and Pulse Rate) as a composite outcome measure of Safety and Tolerability		Change from baseline to day 5 (2 hours post dose)	No
Secondary	Composite outcome measure consisting of multiple pharmacokinetics measures (Area Under the plasma concentration-time Curve (AUC), Plasma elimination half-life (t½), Time to maximum plasma drug concentration (Tmax), and Peak Plasma Concentration (Cmax))		Blood sampling day 1 up to 24 hrs post dose and day 5 up to 24 hrs post dose	No